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Abstract
Patient samples are unique and often irreplaceable. This allows biobanks to be a valuable
source of material. The aim of this study was to assess the ability of Raman spectroscopy to
screen for histologically confirmed cases of Cervical Intraepithelial neoplasia (CIN) using
biobanked liquid based cytology (LBC) samples. Two temperatures for long term storage
were assessed; 80oC and -25oC. The utility of Raman spectroscopy for the detection of CIN
was compared for fresh LBC samples and biobanked LBC samples. Two groups of samples
were used for the study with one group associated with disease (CIN3) and the other
associated with no disease (cytology negative). The data indicates that samples stored at 80oC are not suitable for assessment by Raman spectroscopy due to a lack of cellular material
and the presence of cellular debris. However, the technology can be applied to fresh LBC
samples and those stored at -25oC and is, moreover, effective in the discrimination of
negative samples from those where CIN 3 has been confirmed. Pooled fresh and biobanked
samples are also amenable to the technology and achieve a similar sensitivity and specificity
for CIN 3. This study demonstrates that cervical cytology samples stored within biobanks at
temperatures that preclude cell lysis can act as a useful resource for Raman spectroscopy and
will facilitate research and translational studies in this area

Introduction
Every year millions of cervical Pap tests are performed throughout the world in countries for
purposes of cervical screening. Most Pap tests are performed through use of liquid based
cytology (LBC) where cervical cells are collected before deposition into a volume of liquid
preservative. As not all the material is required for cytological assessment, the surplus, which
would ordinarily be discarded, can be stored within tissue biobanks with due process of
governance. Biobanks constitute a valuable source of material which may support a number
of studies including those on the natural history of disease, evaluation of screening practices,
vaccination effectiveness or the development of new technologies to support screening and
disease management[1-3].
There were an estimated 527,600 new cervical cancer cases and 265,700 deaths from cervical
cancer worldwide in 2012[4]. This demonstrates the importance of both cervical screening to
reduce the burden of disease and also investment in research into new technologies that can
improve the performance and “reach” of cervical screening Different collection media for
liquid based cytology exist however one of the more common media is PreservCyt (Hologic).
PreservCyt is a methanol based solution that preserves cell morphology via fixation. Fixation

is routinely employed as it allows a “snapshot” of a cell’s physical and biochemical state to
be assessed .Methanol is an organic solvent that preserves cells through dehydration and
precipitation of proteins [5]. Fixation is important given that sample collection and assessment
is not performed concurrently. In addition to supporting routine screening, fixation of cells
also supports longer term storage of residual material in biobanks.
The advantage of the Pap test is that it is a widely accepted screening based test with a high
specificity of 95-98% and a sensitivity of 74-96%[6]. The variability in the rates of sensitivity
are due to sampling technique and the variability of the cytology based screening. This can
result in unnecessary gynaecological referral and patient recall. Persistent infection with high
risk human papillomavirus (HPV), is accepted as the major cause of cervical pre-cancer and
cancer [7]. HPV DNA testing has a higher sensitivity (>95%) but lower specificity (~ 84%)
than the Pap test[7].These tests are expensive, time-consuming and provide no information on
cervical cytopathology.
Current methods for detection of cervical cancer and pre-cancer (CIN) are limited and there is
an unmet clinical need for new screening or diagnostic tests. Recently Raman spectroscopy
has shown potential as a tool for screening and diagnosis of cervical lesions and cancer [8-10].
Raman spectroscopy is based on inelastic light scattering where a sample is illuminated by a
monochromatic laser light and interactions between the incident photons and molecules in the
sample result in the scattering of the light. The coupling of the light generates vibrations
within the sample which are characteristic of the chemical structure. This means that the
position, peaks and shape of the Raman bands carry information about the molecular makeup
of the sample. The Raman spectrum of cells and tissues is made up of contributions from

many biochemical components including DNA, RNA, proteins, lipids and carbohydrates [11].
Raman spectroscopy can offer a label free non-destructive method for cervical cancer
screening. It is an objective method, less reliant on operator performance than cytology and
potentially more specific than HPV testing.
Due to confounding factors such as sample collection, blood contamination and sample
variability, few studies have been performed using Raman spectroscopy on cervical cytology
samples and none to our knowledge have investigated the potential of utilising biobanked
LBC samples. The aim of this feasibility study was to assess the utility and performance of
Raman spectroscopy for the detection of CIN using biobanked LBC samples. Samples stored
at -80oC and -25oC were assessed and the ability of Raman spectra to delineate disease from
no disease was determined. Additionally, Raman spectroscopy was assessed in un-banked
LBC samples as a comparator.
Materials and Methods
Sample collection
Two classes of samples were used for the study, classed as disease and no disease. Samples
with no disease were defined as cytology negative and HPV negative whereas samples with
disease were those associated with a histologically confirmed CIN3 with a HPV positivity
according to HPV DNA and mRNA status. All samples were recruited from patients
presenting at a colposcopy clinic for the first time, and had no prior history of disease.
Samples were collected from each patient according to the standard operating procedure
issued by Cervical Check Irelands national cervical cancer screening programme and the
NHS Scottish cervical screening programme. Both procedures are similar and all samples
were biobanked using the same methodology.
133 samples were used in total for this study of which 64 were LBC biobanked samples; 32
with no disease (cytology negative) and 32 with disease (CIN 3). Biobanked samples were

provided by the Scottish HPV Archive, a research tissue biobank set up to facilitate HPV
associated research.
Ethical approval for use of the samples was obtained from the East of Scotland Research
Ethics Service - Tayside committee. Biobanked LBC samples used for this study had been
sedimented with the cellular pellet transferred into a 4.5 ml vial for long term storage in
PreservCyt. After transit, samples were re-constituted to a volume of 20 ml fresh PreservCyt
solution to resemble the original LBC specimen from which the sample was derived.
A further 64 non biobanked “fresh” LBC samples, 32 with no disease (cytology negative) and
32 with disease (CIN 3), were collected in PreservCyt solution from the Coombe Women and
Infants University Hospital (CWIUH), Dublin, Ireland, as part of routine cytological
screening. Ethical approval for use of anonymised samples for the study was granted by the
CWIUH Research Ethics Committee (no. 28-2014). A further 5 fresh LBC samples with
disease (CIN 3) were collected and split into two separate vials. One vial from each sample
underwent the standard biobanking process and was stored for 3 weeks, while the other was
stored at room temperature.

ThinPrep
The samples were then prepared using the ThinPrep 2000 processor (Hologic Inc.,
Marlborough, MA 01752). The ThinPrep process begins with the patient’s gynaecological
sample being collected by the clinician using either a cervical broom or brush. The brush/broom
is then rinsed in the specimen vial containing PreservCyt transport medium

(ThinPrep Pap Test; Cytyc Corportation, Boxborough, Mass). The ThinPrep sample vial is then
capped, labelled and sent to the lab to be processed. The ThinPrep processor homogenizes the
sample by spinning the filter, creating shear forces that breaks up any clumped material (blood,
mucin and non-diagnostic material). The cells are then transferred onto a polycarbonate filter
membrane of the TransCyt filter and transferred onto a glass slide to produce a circular
monolayer of cells approx. 20 mm in diameter. The slide is then ejected into a fixative bath of
95% ethanol
Raman spectroscopy
All Raman analysis was performed using a HORIBA Jobin Yvon XplorRA system (Villeneuve
d’Ascq,France), which incorporates an Olympus microscope BX41 equipped with a X100
objective (MPlan, Olympus, NA = 0.9). A 532 nm diode laser source was used. Laser power
was set to 100% resulting in 16 mW at the objective. The confocal hole coupled to a slit aperture
of 100 µm, was set at 100 µm, for all the measurements. The system was precalibrated to the 520.7 cm-1 spectral line for silicon. A 1200 lines per mm grating was used.
The backscattered light was measured using an air-cooled CCD detector (Andor, 1024x256
pixels). The spectrometer was controlled by Labspec V6.0 software. Two accumulations of 30
seconds were performed on each cell nucleus selected. Raman spectra were acquired from the
nuclei of 20 randomly selected morphologically normal superficial and intermediate cells from
each unstained Pap smear.
Data pre-processing and analysis
Data was normalised and analysed using Matlab software (Mathworks) and specific scripts
developed and adapted for uploading of the spectra and their pre-processing, including

smoothing (Savitzky-Golay K=5, K=13), baseline correction (Rubberband) and vector
normalization. The spectra were also corrected for the glass background using a linear leastsquares method with non-negative constraints (NNLS). The least-squares model was developed
using spectra from the Thinprep glass slides and selected pure biochemicals (e.g., actin,
glycogen, RNA, DNA, etc.) that approximate the biochemical composition of cervical cells.
The data was mean centred and subjected to partial least squares discriminant analysis (PLSDA). PLS-DA involves the creation of latent variables to maximise the co variation between
known datasets and the response variable which they are regressed against. PLS-DA is a form
of analysis that has the ability to distinguish between known classifications of samples and its
aim is to find latent variables and directions to maximise separation in a
multivariate space [12]. To validate the method, leave one patient out cross validation was
performed which involved data from one patient sample being removed from the model, with
this process repeated until all patient samples were left out once
Results
-25oC Vs -80oC biobanked LBC samples
The samples stored at -25oC presented with intact cellular morphology (Figure 1(A)) and
allowed for high quality spectra to be recorded (Figure 1(B)). The samples stored at -80oC
presented with cell lysis, cellular debris and very little cellular material which prevented the
recording of spectra (Figure 1(C)). One possible explanation for this, is the freeze thaw effect
which is commonly used to lyse bacteria and mammalian cells. Storing cells at -80 oC in
PreservCyt without any Dimethyl Sulfoxide and bring up to room temperature can cause the

cells to contract during the thawing process resulting in cell lysis. As a result, only biobanked
samples previously stored at -25oC were used for this study.
Negative Vs CIN 3 (fresh LBC samples) Model
In order to determine if biobanked LBC samples could be used to discriminate no disease
(cytology negative) from disease (CIN 3) using Raman spectroscopy, fresh (non biobanked)
LBC samples were first examined as a control. Figure 2(A) shows mean spectra of Negative
Vs CIN 3. Figure 2(B) is a latent variables (LV) scores scatter plot of LV1 and LV2 which
shows good discrimination along LV1 and LV2. The loadings shown in Figure 2(C), show
that the discrimination is based around Raman peaks at 484 (glycogen), 575 (glycogen), 881
(nucleic acids), 1004 (proteins Phenylalanine), 1139, 1238 (proteins Amide III), 1487
(proteins), 1575 (nucleic acids), 1605 (proteins) and 1669 cm-1 (proteins Amide I). The LV2
loadings show discrimination is based around 1238 (proteins), 1381 (glycogen), 1450
(proteins and lipids), 1642 (proteins) and 1669cm-1 (proteins) (see table 1) [13]. The PLS-DA
prediction plot shown in Figure 2(D) and has a sensitivity of 86% and a specificity of 90%
for CIN 3.

Negative Vs CIN 3 (Biobanked LBC samples) Model
In order to determine if the biobanked samples can be used in a similar fashion to the fresh
samples, negative and CIN3 biobanked samples were compared. Figure 5.3(A) shows the
mean spectra of biobanked Negative samples Vs CIN 3. Figure 5.3(B) is a latent variables
(LV) scores scatter plot of LV1 and LV2 which shows good discrimination along LV1 and

LV2.The loadings from LV1 are shown in Figure 5.3(C) and show that discrimination is
based around Raman peaks, 622 (proteins), 640 (proteins),775 (proteins), 850 (proteins),
1122 (proteins),1152 (proteins), 1207 (proteins), 1450 (proteins), 1560 (proteins), 1605
(proteins), 1642 (proteins) and 1669 cm-1 (proteins). LV2 loadings show discrimination is
based on 1123 (proteins, lipids, carbohydrates), 1338 (proteins) and 1605 cm-1 (proteins)
Raman peaks assigned to phenylalanine 1004 cm-1 show a slight shift between 1003-1004 cm1

which is most likely attributed to the methanol based fixation method which suggests a

change in the conformation of the phenylalanine protein[14]. The PLS-DA prediction plot
shown in Figure 5.3(D) and has a sensitivity of 91% and a specificity of 92% for CIN 3.
Biobanked Vs non-Biobanked samples
5 fresh CIN 3 patient samples were split into two separate vials. One vial from each sample
was frozen as described earlier and the other stored at room temperature. Figure 4(A) show
the mean spectra for biobanked CIN 3samples and the same samples kept at room
temperature for 3 weeks after collection. The mean spectra appear identical. There does not
appear to be a difference between the fresh and biobanked samples. The latent variable
scatter scores plot (Figure 4(B)) shows slight discrimination between the sample types which
is most likely due to internal sample variability[15] (LBC samples are variable by nature) and
the low number of spectra recorded (60 for room temperature/biobanked). The PLS-DA
prediction plot (Figure 4(C)) has a sensitivity of 29% and specificity of 88% for biobanked
samples indicating poor discrimination between the two groups.
Mixed Model

In order to determine if we could mix fresh and biobanked samples together and still achieve
a sensitivity and specificity similar to the fresh and biobanked models, 15 biobanked CIN 3
samples were mixed with 15 fresh CIN 3 samples and compared with 15 negative
biobanked/ 15 fresh negative samples. Figure 5(A) shows the latent variable scatter scores
plot of the model and we can see clear discrimination between the sample types across LV1
and LV2. The LV1 loadings (Figure 5(B)) show that discrimination is based on 482,
(glycogen), 1443 (proteins, lipids) 1487 (proteins), 1605 (proteins) 1669cm-1 (proteins) while
LV2 shows the discrimination is based around 486 (glycogen), 851 (proteins), 1152
(proteins), 1381 (glycogen), 1450 (proteins/lipids), 1575 (nucleic acids) and 1669 cm-1
(proteins). The loadings show similarities to both the fresh and biobanked loadings, but
overall show that glycogen and proteins are the main discriminating factor between negative
and CIN 3 samples. PLS-DA prediction plot has a sensitivity of 94% and a specificity of
95% for CIN 3 (Figure 5(C)).

Discussion
From the results it is clear that samples biobanked at -80oC are not suitable for screening
using Raman spectroscopy due to a lack of cellular material and the presence of cellular
debris.
Spectral differences between fresh negative and CIN 3 samples were observed with regards
to glycogen, nucleic acids and proteins. CIN 3 cells often contain little to no glycogen, hence
the use of Lugol’s solution to visualise abnormal cells in colposcopy [16]. The discrimination
associated with changes in proteins and DNA is consistent with the neoplastic changes that
occur in CIN 3 supported by persistent HPV infection such as increased cell cycling with
coincident increase in replication and levels of nucleic acids [15]. The PLS-DA prediction plot
gives a sensitivity of 86% and a specificity of 90% for CIN3.
Negative Vs CIN 3 biobanked sample results showed that discrimination was driven solely by
proteins. Raman peaks associated with nucleic acids/ DNA are not as strongly present as
they are in the non-biobanked samples. Long term storage of biobanked samples is likely to
have led at least to an element of nucleic acids degradation which would explain why nucleic
acid is not discriminatory between negative and CIN3 samples. However the PLS-DA
prediction plot (Figure 3(D)) does show slightly higher sensitivity (91%) and specificity
(92%) rates when compared to fresh samples (86% sensitivity and 90% specificity) indicating
that biobanking at -20oC does not preclude discrimination of negative and CIN 3 samples on
Raman spectroscopy.

The same patient samples that had been split in two with half biobanked and the other half
stored at room temperature showed no discrimination between the samples. Hence the 3 week
period of biobanking at -20oC had no detrimental effects on the physical or biochemical
properties of the samples. The mixed model showed that biobanked and fresh LBC samples
could be combined with an improved sensitivity of 94% and specificity of 95%. A limitation
of this study is the inability to use biobanked LBC samples stored at -800C for Raman
spectroscopic analysis as most biobanks will have samples stored at -800C for long term
storage[3] hence the true potential of using biobanks as a source of patient samples could be
lost. Further research in this area should involve the use of different biobank specimens
(bronchial and thyroid fine needle aspirations) to investigate any detrimental effects the
biobanking process may have on cytological specimens17 18.

Conclusion
Raman spectroscopy can effectively discriminate disease free cervical LBC samples from
those with disease (CIN 3) and this is possible using biobank cervical LBC samples stored at
-25oC. Pooling samples stored at -25 oC with fresh samples does not affect the sensitivity and
specificity of Raman spectroscopy for the discrimination of disease. This study demonstrates
that biobanks of cervical LBC samples are a useful resource for future Raman spectroscopy
studies and will facilitate the further assessment of this technology which shows highly
encouraging performance for the detection of cervical dissease
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Figure 1 (A) LBC samples stored at -25oC present with intact cellular morphology.
Note the presence of superficial and intermediate cells on the unstained slide which were
selected for Raman spectral recording. (B) High quality spectra recorded from
morphologically normal intermediate and superficial cells in the spectral range 400-1800cm1

. (C) LBC samples stored at -80oC. Note lack of cellular material and presence of cellular

debris.
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Figure 2 (A) mean spectra of fresh Negative (red) Vs CIN 3 (blue). (B) is a latent variables
(LV) scores scatter plot of LV1 and LV2, TN (yellow) Vs CIN 3 (blue). (C) LV1(blue) and
LV2 (orange) loadings (D) PLS_DA prediction plot CIN 3 (blue), negative (yellow)
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Figure 3 (A) mean spectra of biobanked Negative (red) Vs CIN 3 (blue). (B) latent variables
(LV) scores scatter plot of LV1 and LV2, TN (yellow) Vs CIN 3 (blue). (C) LV1 (blue) LV2
(orange) .(D) PLS_da prediction plot CIN 3 (blue), negative (yellow) .
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Figure 4 (A) mean spectra of fresh CIN 3 (blue) vs biobanked CIN 3 (red). (B) latent
variables (LV) scores scatter plot of LV1 and LV2, fresh CIN 3 (yellow) Vs biobanked CIN
3.(C) PLS-DA prediction plot biobanked CIN 3 (blue) vs fresh CIN 3 (yellow).
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Figure 5 (A) latent variables (LV) scores scatter plot of LV1 and LV2, TN (yellow) Vs CIN 3
(blue). (B) LV1 loadings (blue) and LV2 loadings (orange). (C) PLS-DA prediction plot CIN
3 (blue), negative (yellow)
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